133 related articles for article (PubMed ID: 37526191)
1. Evaluation of Therapeutic Mechanism of Hedyotis Diffusa Willd (HDW)‒ Scutellaria Barbata (SB) in Clear Cell Renal Cell Carcinoma
Bai Y; Chen R; Sun J; Guo Y
Comb Chem High Throughput Screen; 2024; 27(6):910-921. PubMed ID: 37526191
[TBL] [Abstract][Full Text] [Related]
2. Exploring the mechanisms of anti-ovarian cancer of Hedyotis diffusa Willd and Scutellaria barbata D. Don through focal adhesion pathway.
Xu X; Chen F; Zhang L; Liu L; Zhang C; Zhang Z; Li W
J Ethnopharmacol; 2021 Oct; 279():114343. PubMed ID: 34147618
[TBL] [Abstract][Full Text] [Related]
3. Investigating the Multi-Target Pharmacological Mechanism of
Song Y; Wang H; Pan Y; Liu T
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31600936
[No Abstract] [Full Text] [Related]
4. Network pharmacology and experimental validation to identify the potential mechanism of Hedyotis diffusa Willd against rheumatoid arthritis.
Deng H; Jiang J; Zhang S; Wu L; Zhang Q; Sun W
Sci Rep; 2023 Jan; 13(1):1425. PubMed ID: 36697436
[TBL] [Abstract][Full Text] [Related]
5. Exploring the mechanism of action of Hedyotis diffusa Willd on acne using network analysis.
Seo G; Kim K
Medicine (Baltimore); 2023 Mar; 102(12):e33323. PubMed ID: 36961163
[TBL] [Abstract][Full Text] [Related]
6. [Mechanism of "Scutellaria barbata-Hedyotis diffusa" against breast cancer based on network pharmacology].
Jing XU; Feng-Qin S; Ke-Xin DU; Jia D; Dong-Yun LI
Zhongguo Zhong Yao Za Zhi; 2020 Sep; 45(18):4448-4454. PubMed ID: 33164375
[TBL] [Abstract][Full Text] [Related]
7. Identification of Hedyotis diffusa Willd-specific mRNA-miRNA-lncRNA network in rheumatoid arthritis based on network pharmacology, bioinformatics analysis, and experimental verification.
Jiang J; Huang M; Zhang SS; Wu YG; Li XL; Deng H; Qili XY; Chen JL; Meng Y; Sun WK
Sci Rep; 2024 Mar; 14(1):6291. PubMed ID: 38491124
[TBL] [Abstract][Full Text] [Related]
8. Network-based pharmacology-based research on the effect and mechanism of the Hedyotis diffusa-Scutellaria Barbata pair in the treatment of hepatocellular carcinoma.
Hou C; Wen X; Yan S; Gu X; Jiang Y; Chen F; Liu Y; Zhu Y; Liu X
Sci Rep; 2024 Jan; 14(1):963. PubMed ID: 38200019
[TBL] [Abstract][Full Text] [Related]
9. Scutellaria barbata and Hedyotis diffusa herb pair for breast cancer treatment: Potential mechanism based on network pharmacology.
Ma TT; Zhang GL; Dai CF; Zhang BR; Cao KX; Wang CG; Yang GW; Wang XM
J Ethnopharmacol; 2020 Sep; 259():112929. PubMed ID: 32416245
[TBL] [Abstract][Full Text] [Related]
10. Hedyotis diffusa Willd and Astragalus membranaceus May Exert Anti-colon Cancer Effects by Affecting AKTI Expression, as Determined by Network Pharmacology and Molecular Docking.
Ren J; Mo Z; Huang Z; Li S
Curr Comput Aided Drug Des; 2024 Apr; ():. PubMed ID: 38638040
[TBL] [Abstract][Full Text] [Related]
11. The protective capability of
Li Y; Ding T; Chen J; Ji J; Wang W; Ding B; Ge W; Fan Y; Xu L
Front Immunol; 2022; 13():943827. PubMed ID: 35958622
[TBL] [Abstract][Full Text] [Related]
12. Scutellaria barbata D.Don and Oldenlandia diffusa (Willd.) Roxb crude extracts inhibit hepatitis-B-virus-associated hepatocellular carcinoma growth through regulating circRNA expression.
Yang PW; Chen TT; Zhao WX; Liu GW; Feng XJ; Wang SM; Pan YC; Wang Q; Zhang SH
J Ethnopharmacol; 2021 Jul; 275():114110. PubMed ID: 33864890
[TBL] [Abstract][Full Text] [Related]
13. Molecular Targets and Mechanisms of Hedyotis diffusa Willd. for Esophageal Adenocarcinoma Treatment Based on Network Pharmacology and Weighted Gene Co-expression Network Analysis.
Zhuang Y; Sun YG; Wang CG; Zhang Q; Che C; Shao F
Curr Drug Targets; 2024 Jan; ():. PubMed ID: 38213161
[TBL] [Abstract][Full Text] [Related]
14. The anti-tumor effect and bioactive phytochemicals of Hedyotis diffusa willd on ovarian cancer cells.
Zhang L; Zhang J; Qi B; Jiang G; Liu J; Zhang P; Ma Y; Li W
J Ethnopharmacol; 2016 Nov; 192():132-139. PubMed ID: 27426510
[TBL] [Abstract][Full Text] [Related]
15. Synergistic action of Hedyotis diffusa Willd and Andrographis paniculata in Nasopharyngeal Carcinoma: Downregulating AKT1 and upregulating VEGFA to curb tumorigenesis.
Ye C; Zhang B; Tang Z; Zheng C; Wang Q; Tong X
Int Immunopharmacol; 2024 May; 132():111866. PubMed ID: 38603854
[TBL] [Abstract][Full Text] [Related]
16. Antitumor potential of Hedyotis diffusa Willd: A systematic review of bioactive constituents and underlying molecular mechanisms.
Han X; Zhang X; Wang Q; Wang L; Yu S
Biomed Pharmacother; 2020 Oct; 130():110735. PubMed ID: 34321173
[TBL] [Abstract][Full Text] [Related]
17. The Antitumor Constituents from Hedyotis Diffusa Willd.
Wang C; Zhou X; Wang Y; Wei D; Deng C; Xu X; Xin P; Sun S
Molecules; 2017 Nov; 22(12):. PubMed ID: 29189741
[TBL] [Abstract][Full Text] [Related]
18. Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology.
Zheng J; Xu W; Liu W; Tang H; Lu J; Yu K; Song X; Li F; Wang Y; Wang R; Chen L; Zhang H; Qiu Y; Wei G; Zhou X; Yang J
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34002799
[TBL] [Abstract][Full Text] [Related]
19. The anti-inflammatory effects of Hedyotis diffusa Willd on SLE with STAT3 as a key target.
Xu L; Li Y; Ji J; Lai Y; Chen J; Ding T; Li H; Ding B; Ge W
J Ethnopharmacol; 2022 Nov; 298():115597. PubMed ID: 35940466
[TBL] [Abstract][Full Text] [Related]
20. Systems pharmacology uncover the mechanism of anti-non-small cell lung cancer for Hedyotis diffusa Willd.
Su X; Li Y; Jiang M; Zhu J; Zheng C; Chen X; Zhou J; Li Y; Xiao W; Wang Y
Biomed Pharmacother; 2019 Jan; 109():969-984. PubMed ID: 30551551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
